Post-earnings recap
Reported
Tue, Nov 10, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is facing significant challenges, as evidenced by the substantial EPS miss. The stock reacted negatively, dropping 3.85%, reflecting investor concerns about the company's performance and lack of guidance. Without clear revenue figures or future expectations, uncertainty remains high for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | -98.78% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide specific forecasts.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.